Skip to main
AKTX

Akari Therapeutics (AKTX) Stock Forecast & Price Target

Akari Therapeutics (AKTX) Analyst Ratings

Based on 3 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Akari Therapeutics PLC is positioned favorably due to its lead product candidate, AKTX-101, which has shown promising activity against various cancer types in preclinical studies. The ability of AKTX-101 to generate immunological memory and enhance tumor recognition aligns well with contemporary immuno-oncology trends, suggesting a potential for significant therapeutic advancements. Additionally, the company's innovative ADC platform, utilizing proprietary cancer-killing toxins, has the potential to achieve best-in-class outcomes, particularly when combined with existing immunotherapies, potentially enhancing overall efficacy and safety in cancer treatment.

Bears say

Akari Therapeutics PLC faces a challenging financial outlook primarily due to its weak balance sheet, which raises significant risks regarding its operational viability. The company is under pressure to secure additional funding to support its ongoing and planned preclinical and clinical programs, contributing to a financial overhang that may negatively impact its stock price. Despite the promise of its ADC platform, the lack of sufficient financial resources to advance its lead candidate, AKTX-101, adds to concerns about the company's ability to remain competitive in the oncology market.

Akari Therapeutics (AKTX) has been analyzed by 3 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Akari Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Akari Therapeutics (AKTX) Forecast

Analysts have given Akari Therapeutics (AKTX) a Strong Buy based on their latest research and market trends.

According to 3 analysts, Akari Therapeutics (AKTX) has a Strong Buy consensus rating as of Jan 10, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $2.53, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $2.53, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Akari Therapeutics (AKTX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.